United States· US:66621-0150_d0c33dec-842e-4cc0-9d8f-515d6efd8a0c
ANASCORP
A medicinal product containing centruroides fab2 antivenin (equine), registered in United States by Rare Disease Therapeutics, Inc.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CENTRUROIDES FAB2 ANTIVENIN (EQUINE)
- Manufacturer
- Rare Disease Therapeutics, Inc
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1166621015021 VIAL in 1 CARTON (66621-0150-2) / 10 mL in 1 VIAL (66621-0150-1)
- ndc1166621-0150-2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d2dd6727-469c-4f13-a883-4cc6a0aac8af GET /v1/drugs/d2dd6727-469c-4f13-a883-4cc6a0aac8af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "7",
"substance": "CENTRUROIDES FAB2 ANTIVENIN (EQUINE)",
"productndc": "66621-0150",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA125335",
"marketing_category": "BLA"
}See everything about centruroides fab2 antivenin (equine).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.